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Abstract: Cancer continues to be a leading source of morbidity and mortality worldwide in 
spite of progress in oncolytic therapies. In addition, the incidence of cancers affecting the 
breast, kidney, prostate and skin among others continue to rise. Chemotherapeutic drugs 
are widely used in cancer treatment but have the serious drawback of nonspecific toxicity 
because these agents target any rapidly dividing cell without discriminating between healthy 
and malignant cells. In addition, many neoplasms eventually become resistant to 
conventional chemotherapy due to selection for multidrug-resistant variants. The limitations 
associated with existing chemotherapeutic drugs have stimulated the search for new 
oncolytic therapies. Host defense peptides (HDPs) may represent a novel family of 
oncolytic agents that can avoid the shortcomings of conventional chemotherapy because 
they exhibit selective cytotoxicity against a broad spectrum of malignant human cells, 
including multi-drug-resistant neoplastic cells. Oncolytic activity by HDPs is usually via 
necrosis due to cell membrane lysis, but some HDPs can trigger apoptosis in cancer cells 
via mitochondrial membrane disruption. In addition, certain HDPs are anti-angiogenic 
which may inhibit cancer progression. This paper reviews oncolytic HDP studies in order 
to address the suitability of selected HDPs as oncolytic therapies. 
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1. Introduction 
The human immune system mainly recognizes and eliminates malignant cells via receptor-mediated 
mechanisms. The immune response can play a significant role in controlling malignant growth under 
natural conditions or in response to therapeutic manipulation, but malignant cells may evade immune 
surveillance [1,2]. 
Conventional cytotoxic therapies, such as radiation and chemotherapy, are the methods of choice 
for cancer management. Radiation therapy is relatively precise and used to achieve local control, 
whereas chemotherapy exerts a systemic effect and is used as a broad array of cancer treatment. 
However, both therapies have low therapeutic indices and are often highly toxic with a broad spectrum 
of severe side effects. Numerous chemotherapeutic drugs have been developed to treat cancers, 
including DNA-alkylating agents, antimetabolites, and hormone agonists/antagonists. Although these 
drugs have been successfully used for the treatment of metastatic cancers, severe side-effects and dose 
limitations are prevalent. This is because they are nonspecific and target any rapidly dividing cell 
without discriminating between healthy and malignant cells [3]. 
Moreover, cancer cells develop resistance to the available chemotherapeutic  that is mediated by the 
overexpression of multidrug-resistance proteins that pump the drugs out of cells and thus render the 
drugs ineffective [4]. In addition, many neoplasms eventually become resistant to conventional 
chemotherapy due to selection for multidrug-resistant variants [5]. The limitations associated with 
existing chemotherapeutic drugs have stimulated the search for new oncolytic agents with new modes 
of action. 
A promising family includes host defence peptides (HDPs) that recently have received attention  
as alternative chemotherapeutic agents that overcome the limits of current drugs. These peptides   
have several advantages over currently used oncolytic therapeutics, such as selective cytotoxicity   
for cancer cells, ability to bypass the multidrug-resistance mechanism, and additive effects in 
combination therapy [6]. 
1.1. Host Defense Peptides 
HDPs are ubiquitous in nature. They have been found in animals as diverse as insects and human. 
Recent developments highlight the importance of vertebrate epithelial cells as sites of HDPs 
production and suggest a critical role for this system in human health and disease. Gene-encoded 
HDPs are found widely in the animal kingdom and salient examples include the cecropins from 
insects, magainins, temporins and dermaseptins from amphibians, and defensins from mammals [7–13]. 
These molecules tend to exhibit intrinsic specificity for microbial invaders and are relatively much less 
toxic for the metazoan host’s cells. However, some are also active on eukaryotic cells. This specificity 
endows the animal with an “innate” immunity, in contrast to the better studied acquired immunity 
conferred by the clonal expansion of B and T cells. The possible importance of this system as a check 
on infection is evident when one considers that most bacteria have generation times of 20–30 min 
whereas the mounting of a specific immune response, dependent on the growth of mammalian cells, 
may take days or weeks. Int. J. Mol. Sci. 2011, 12                 
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HDPs, capable of destroying prokaryotic and eukaryotic cell membrane attract peoples’ attention as 
they have different mechanism than the currently available drugs, which makes them candidates for 
novel therapeutic approaches. 
1.2. Structure and Mechanism of Action 
More than 1000 native HDPs have been isolated so far and they do not share a specific molecular 
composition, size, or a conformational structure. Their size vary between ~12–50 amino acids, some 
are linear and adopt α-helical or β-sheet structures in the presence of membranes, while others have 
specific folds due to the presence of disulfide bonds (e.g., defensins) [14–17]. Nevertheless, despite 
their structural diversity they have hallmark physical features of a high net positive charge and a 
threshold of hydrophobicity that allows them to adopt an amphipathic structure and to interact with  
the membrane of the microbes. HDPs are typically surface and membrane active agents that kill 
various cells by binding and disrupting the structural integrity of the cell membrane and as a result the 
homeostatic mechanisms of the target cell [9,18,19]. 
The positive charges serve to attract the antibiotic to the surface of the target microbe. The remarkable 
selectivity of these peptides is thought to be due to the relative abundance of negative charges in target 
cell membranes compared to those of the metazoan host. These membrane charges are due primarily to 
anionic phospholipids [18,19]. Such charges act as the “receptors” for the highly cationic HDOs. The 
amphipathic nature of the antibiotics is also a critical feature and allows them to insert into the membrane 
and permeate it via the formation of pores, holes, or ion channels [20]. Membrane permeation can take 
place via different mechanisms such as the “barrel stave” or the “carpet” to form organized channels or 
intermediate “toroidal” pores, respectively before membrane disintegration. Nevertheless, the exact 
molecular mechanism depends upon the specific molecule used [6,21]. 
The presence of cholesterol in host cell membranes may serve to protect them from the disruptive 
effects of the HDPs. Since microbes lack cholesterol in their membranes this phenomenon probably 
further increases the selectivity of these HDPs. In many instances cells with a higher transmembrane 
potential are more susceptible to the killing effects of HDPs. Such a potential, being negative on the 
inside of the cell, may provide an electromotive force that aids in driving the integration of the 
positively charged HDP into the target membrane [18]. There is an ample of evidence that the activity 
of most HDPs in not receptor mediated. For example, the fact that synthetic HDPs consisting of all  
D amino acids [21–23], both D- and L- amino acids or scrambled sequences [24,25] are as biologically 
active as their L amino acid containing counterparts. This observation underscores the uniqueness of 
the mechanism of action of HDPs as compared to most pharmaceuticals, which are direct inhibitors of 
enzymes with chiral active sites. 
The oncolytic mechanisms of HDPs include: (i) triggering of necrosis via the cell membrane   
lytic effect [26–29]; (ii) trigger apoptosis via mitochondrial membrane disruption [26,27]; and   
(iii) non-membranolytic modes of action. Similar to prokaryotic cells, many cancer cells have a higher 
content of anionic phospholipids on their outer leaﬂet relative to normal eukaryotic cells. It has been 
demonstrated that HDPs induce cell death of transformed cells, but are much less cytotoxic to   
non-transformed cells [7,9,28–38]. Int. J. Mol. Sci. 2011, 12                 
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These results suggest that HDPs may have future value as oncolytic drugs either alone or in 
combination with conventional therapies. The mechanisms of action of HDPs against prokaryotic cells 
have been widely investigated, while much less is known regarding the interactions with and effects on 
eukaryotic cells [14,19,39–41]. 
Pro-apoptotic effects induced by HDPs that are conjugated to a functional domain, which allow 
receptor-mediated or receptor-independent internalization in eukaryotic cells, have been reported. After 
internalization these HDP conjugates caused mitochondrial membrane disruption resulting in 
cytochrome c release and induction of apoptosis [27,42]. Other types of HDPs translocate spontaneously 
into the cell cytoplasm where they depolarize the inner mitochondrial membrane. Whether the 
mitochondria in intact cells are disrupted as a result of a direct effect of the HDPs is unknown [43,44]. 
Exploiting the oncolytic properties of HDPs may embody a new paradigm for therapy of 
neoplasms. Despite the evidence that HDPs can play a significant role in controlling neoplastic growth, 
the cascade of molecular events leading to oncolytic activity remains to be fully elucidated (Figure 1). 
Nevertheless, some recent advances might drastically change the way of designing the next generation 
of cancer vaccines, hopefully improving the effectiveness of this therapeutic approach. 
Figure 1. Potential functions of host defense peptides (HDPs) in cancer. 
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2. α-Helical Oncolytic Peptides 
2.1. BMAP-27 & BMAP-28 
There is evidence that these bovine cathelicidin-derived HDPs are cytotoxic and cause apoptosis of 
both freshly isolated leukaemia cells and certain human leukaemia cell lines [43,45,46]. Unfortunately, 
these HDPs have a narrow therapeutic dose range as low doses are only active against proliferating 
leukaemia cells and not dormant or slowly multiplying leukaemia cells and high doses cause haemolysis 
of benign red and white blood cells [45,46]. 
2.2. Cecropin A and B 
Cecropin A and B belong to the Cecropin-family of antimicrobial peptides which were first isolated 
from the hemolymph of the giant silk moth Hyalophora cecropia [8,14,47]. Cecropins have the ability 
to form amphipathic alpha-helices which allow them to target nonpolar lipid cell membranes. Upon 
membrane targeting, they form ion-permeable channels subsequently resulting in cell depolarization, 
irreversible cytolysis and finally death [48,49]. Ceropin B has been shown to induce pore formation  
in cell walls [50,51]. Although some researchers have suggested that cecropins exert cytolytic activity 
against cancer cells through ion-permeable channel formation in the cell membrane, the precise 
mechanism of the cancer cell-killing action of the peptides remains to be deciphered. Cecropins kill 
neoplastic cells at concentrations lower than those required to lyse normal cells such as erythrocytes, 
fibroblasts and peripheral blood lymphocytes [32,52,53]. 
Studies have demonstrated specific oncolytic activity of both Cecropin A and B against mammalian 
leukemia, lymphoma and colon carcinoma cell lines [32,53,54] as well as small cell lung cancer [55] 
and gastric cancer cells [56]. In vivo, Cecropin B improves survival of mice bearing ascitic colon 
adenocarcinomas [53]. Transfection of human bladder cancer cells with Cecropin genes reduces their 
malignancy in nude mouse models [57]. Cecropin A and B have demonstrated significant inhibition of 
maliganant cell proliferation against bladder cancer cell lines by direct cancer cell lysis, probably by 
target cell membrane disruption [58]. While Cecropin A was able to induce apotosis in leukemia cells [59] 
and HL-60 a promyelocytic cell line [59], Cecropin B has been shown to have oncolytic activity  
in vitro  versus multidrug-resistant human breast and ovarian cancer cell lines and in vivo  versus  
mice with ascitic colon adenocarcinoma cells [53]. Polychemotherapy, of established agents   
5-fluorouracil and cytarabine with cecropin A has a synergistic oncolytic effect on leukemia cells at 
certain doses [52]. 
2.3. LL-37/hCAP-18 
Cathelicidin (LL37) consisting of the linear C terminus of the human CAP-18 molecule, has an  
alpha-helical structure, and interacts with the formyl peptide receptor-like 1 (FPRL1) G protein coupled 
receptor rather than with a chemokine receptor [60,61]. Cathelicidins are a family of antimicrobial 
proteins found in most mammalian species. They consist of a highly conserved N-terminal domain, 
cathelin, and a variable C-terminal peptide, which is proteolytically released upon demand. The single 
human member of this family, 18 kDa human cationic antimicrobial protein, hCAP18, is mainly Int. J. Mol. Sci. 2011, 12                 
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produced by leucocytes and epithelial and mucosal cells. hCAP18 is the pro-protein and LL-37 is the 
mature processed form [62]. A 27-mer peptide of the C-terminal domain (hCAP18 (109–135)) of 
hCAP-18 which corresponds to amino acid residues 6–32 of LL-37, was recently found to induce 
apoptosis in a human oral squamous carcinoma cell line via a mechanism involving mitochondrial 
depolarisation without any detectable activation of caspase-3 [63]. 
It has been proposed that the the oncolytic activity of LL-37/hCAP-18 is due to LL-37(17–29). This 
is a 13 amino acid residue fragment of the COOH-terminal region corresponding to amino acid 
residues 17–29 [64]. This C-terminal domain of hCAP18, hCAP18109–135, induces apoptosis in both 
drug-sensitive and drug-resistant variants of oral squamous cell carcinoma SAS-H1 cells. In the same 
study, hCAP18109–135 had no cytotoxic effects on the HaCaT human keratinocyte cell line or on 
human gingival fibroblasts [63]. 
Unfortunately, LL-37 and its peptide fragments appear to be cytotoxic to the vascular system, being 
cytotoxic to both human peripheral blood leucocytes and untransformed endothelial cells with 
resulting haemolysis [65,66].  
2.4. Magainins 
Magainin II belongs to a family of antimicrobial peptides and was originally isolated from the skin 
of the African clawed frog, Xenopus laevis [67]. These peptides are important components in the 
innate host defense response in a wide range of organisms, from bacteria to humans [68]. Magainin II 
has an amphipatic α-helical structure that enables it to target both negatively-charged and nonpolar 
lipid cell membranes via the formation of toroidal pores, leading to depolarization, irreversible 
cytolysis, and finally to cell death [9,69]. 
Studies have demonstrated a significant cytotoxic effect of magainin II against a wide range of 
cancer cell lines including melanoma, bladder, breast and lung cancers as well as lymphomas and 
leukemias [7,35,70–72]. In vivo, magainins have been shown to improve survival of animals with 
ascites-producing neoplasms [7]. Furthermore, in a subcutaneous xenograft model of malignant 
melanoma growth in nude mice, local treatment of magainin II completely ablated the neoplasm [72]. 
More importantly, the main advantage of magainins is their selectivity for neoplastic versus normal 
cells. Magainin II peptide exerts cytotoxic and antiproliferative efﬁcacy by membrane disintegration in 
bladder cancer cells but has no effect on normal murine or human ﬁbroblasts [70]. 
Magainins kill neoplastic cells at concentrations lower than that required to lyse normal cells such 
as peripheral blood lymphocytes, erythrocytes, and normal murine or human fibroblasts [9,69,70]. 
Additionally, magainins are highly resistant to serum proteolysis [21]. Although some researchers have 
suggested that these peptides exert cytolytic activity against cancer cells through ion-permeable pore 
formation in the cell membrane, the precise mechanism of the cancer cell-killing action of the peptides 
remains to be deciphered. Magainins appear to permeabilise cell membranes differently; by a toroidal 
mechanism in bacterial cells and by the carpet mechanism against mammalian cells [73]. 
The selective oncolytic activity of magainin II has not yet been completely explained. 
Physicochemical attributes of cell membranes such as lipoprotein content and fluidity may explain  
the differences of the magainin effect. It has been suggested that the relatively large amounts of Int. J. Mol. Sci. 2011, 12                 
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anionic substances, such as phosphatidyl serine in tumour cells, may particularly attract cationic 
magainins [7,10,11,18,74,75]. 
The potential of magainin II as an oncolytic drug is enhanced by the fact that its unique mechanism 
of cell killing is unaffected by the multidrug resistance (MDR) phenotype in human melanoma and 
small-cell lung carcinoma [35,76]. Significant oncolytic activity of the structurally and functionally 
related antimicrobial peptide Magainin II has been demonstrated against bladder cancer cell lines   
in vivo [70]. In clinical practice, the continual emergence of drug resistance hinders the activity of 
many standard oncolytic agents. MDR, such as the overexpression of a membrane-bound efflux pump,  
P-glycoprotein [77], renders drugs such as Adriamycin and the vinca alkaloids useless. These drugs 
enter cells by passive diffusion but are actively pumped out of the cell by P-glycoprotein. Magainin II, 
in contrast, has been found to have similar oncolytic activity against chemonaive cells as well as MDR 
cell lines [35,76,77] 
2.5. Mellitin 
Melittin is a HDP consisting of 26 amino acids and is the principal active component of bee venom. 
It is a powerful stimulator of phospholipase A2 and has been shown to speciﬁcally counterselect for 
cells in culture that express high levels of the ras oncogene [78]. However, due to its high toxicity 
against all types of cells it has not been investigated intensively as a potential oncolytic peptide. 
3. Β-Sheet Oncolytic Peptides 
3.1. Defensins 
The defensins can be classified into two subfamilies based on their tertiary structure. They exhibit 
considerable variation in their amino acid sequences, perhaps based on selective pressures to enable them 
to contend with a wide variety of microbial agents. The human defensins, although small (3.5–4 kDa), 
have three intramolecular cysteine bonds linking cysteines 1–6, 2–4, and 3–5, whereas the  defensins 
(4–6 kDa) have bonds between cysteines 1–5, 2–4, and 3–6. Consequently, these small molecules have 
an intricate tertiary structure with a core of three anti-parallel β-sheet components resembling 
chemokines [7,79,80]. 
Similar cysteine-rich HDPs, also called defensins, are found in plants, fungi and invertebrates and 
share many structural features and activities with human α and β-defensins [81]. Humans produce six 
different α-defensins, including 4 peptides (HNP-1 to HNP-4) in neutrophils and 2 peptides (HD5 and 
HD6) in Paneth cells of the small bowel. β-defensins, which are phylogenically older, more basic and 
slightly longer (36 or more amino-acid residues), form a rapidly growing family. The first human  
β-defensin hBD1 was identified in 1995. Five other hBD peptides have been partly characterized in the 
following years and a recent analysis of the human genome identified almost 40 potential coding 
regions for β-defensins [82]. 
α-defensin and β-defensin families do not share DNA sequence similarity or disulfide topology  
but possess highly similar tertiary structures with comparable antimicrobial activity [81]. HNP1 could 
also inhibit angiogenesis by affecting include lung cancers, renal cell carcinomas, squamous cell 
carcinomas of the tongue, bladder carcinomas and endothelial cell proliferation, adhesion and Int. J. Mol. Sci. 2011, 12                 
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migration [83–88]. However, at lower doses, HNP1–3 can also increase the proliferation, motility and 
invasiveness of cancer cell lines [87,89]. HNP-1 is oncolytic against several cancer cell lines, including 
Raji human B-lymphoma cells, human oral squamous carcinoma cells, and MOT mouseteratocarcinoma 
cells [10,11,79,90]. In addition, concentrations of HNP1–3 higher than 25 µg/mL exert cytotoxic effects 
on both eukaryotic cells and cancer cell lines [10,79,88,90], and the presence of α-defensins in tumor 
cells explored by immunohistochemistry is sometimes associated with morphological signs of necrosis 
in surrounding cells [88]. Rabbit macrophage-associated defensins that are homologues of HNP-1   
and -2 are also able to lyse murine cancer cells [91]. 
Cancer cell killing by HNP-1, -2, and -3 involves a membrane binding event, most likely mediated by 
electrostatic interactions, followed by rapid collapse of the membrane potential and loss of membrane 
integrity [10,11]. Membrane permeabilisation by HNPs has been attributed to the channel-forming 
ability of these peptides because HNP-1 has been shown to form voltage-dependent, ion-permeable 
channels in planar phospholipid bilayer membranes [92]. 
HNP-mediated cytotoxicity may also involve DNA damage since single strand DNA breaks were 
detected in HNP-treated target cells, although nucleosome-sized fragments of DNA that are 
characteristic of apoptosis were not observed [93]. In addition to their cytotoxic activity, HNP-1 and -3 
may be able to interfere with neovascularisation during cancer development because these α-defensins 
inhibit the α5β1 integrin-dependent migration and adhesion of endothelial cells to fibronectin in response 
to vascular endothelial growth factor (VEGF) [84]. In addition, HNP-1 and -3 inhibited VEGF-induced 
proliferation of endothelial cells via the induction of apoptosis. Unfortunately, the clinical utility of 
human α-defensins is limited by the fact that HNPs are not cancer-selective, causing the lysis of normal 
human leukocytes, epithelial cells, and fibroblasts [10,94]. Furthermore, intratumoral overexpression of 
HNP-1 mediates inhibition and partially eradication of breast and colon carcinoma by modulation of 
anti-tumor immunity, induction of apoptosis or inhibition of angiogenesis [95]. In addition, serum 
strongly inhibits HNP-mediated cytotoxicity, which poses an obstacle to the systemic administration of 
these human α-defensins [11]. 
Defensins are also potent immunological adjuvants and could be used to overcome the ability   
of malignant cells to evade immunosurveillance [96,97]. For example, defensins recruit dendritic   
cells in organotypic cultures of HPV-transformed keratinocytes maintained in vitro or grafted in vivo, 
suggesting that these molecules may restore some immune functions altered during cervical 
carcinogenesis [98]. Therefore, defensins could be useful in the formulation of therapeutic oncolytic 
vaccines via chemotactic recruitment of dendritic cell precursors that may promote neovascularization, 
in part by undergoing endothelial-like trans-differentiation [99]. α- and β-defensins could provide an 
endogenous balance in angiogenesis regulation, depending on the extent to which recruitment of 
dendritic cells or neutrophils predominates. The anti-angiogenic effects of α-defensins could contribute 
to their antitumour effect [100]. 
In vitro, α-defensins are atypical ligand of α5β1-integrin that specifically inhibits α5β1-integrin-
dependent migration of endothelial cells to fibronectin. They also attenuate the VEGF-stimulated 
increase in endothelial permeability and block endothelial cell proliferation and capillary sprout 
formation in 3-dimensional fibrin-matrices [85]. 
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3.2. Lactoferricin 
Bovine lactoferricin is a peptide fragment produced by acid-pepsin hydrolysis of lactoferrin 
obtained from cow’s milk [101]. Lactoferricin, which consists of amino acid residues 17 to 41 proximal 
to the NH2 terminus of bovine lactoferrin. LfcinB also possesses potent in vivo activity against cancer 
cells [102–104]. Lactoferricin B binds to cancer cell membranes, causing membrane integrity to be lost 
due to the formation of transmembrane pores that allow the HDP to enter the cytoplasmic compartment 
of the malignant cell and co-localize with negatively-charged mitochondria [105,106]. Although mouse 
fibrosarcoma cells and human neuroblastoma cells exposed to lactoferricin B die primarily via necrosis 
caused by a cell membrane lytic effect [105], lactoferricin B kills human leukemia and breast 
carcinoma cells by a process that involves the sequential generation of reactive oxygen species, loss of 
mitochondrial transmembrane potential, and activation of the caspase cascade culminating in cell death 
by apoptosis [104,106]. Whether lactoferricin B-treated cancer cells die by necrosis or apoptosis may 
ultimately be determined by the degree of irreparable lactoferricin B-mediated damage to the 
cytoplasmic membrane relative to mitochondrial membrane damage caused by internalized lactoferricin 
B. Although the cytotoxic activity of lactoferricin B is reduced in the presence of high concentrations of 
serum [104], systemic or intratumoural administration of Lactoferricin B is nonetheless able to inhibit 
the in vivo growth and/or metastasis of several different cancer types in mice [33,104,105]. 
Lactoferricin B has been shown to suppress both basic fibroblast growth factor (bFGF)- and   
VEGF-driven proliferation and migration of human endothelial cells in vitro, as well as interfering 
with bFGF- and VEGF-induced angiogenesis in subcutaneous Matrigel plugs implanted in mice, by 
competing with bFGF and VEGF for growth factor receptor-associated heparan sulfate proteoglycans 
on the endothelial cell surface [106]. 
Administration of lactoferricin B to mice 1 day after intravenous cancer inoculation results in a 
significant inhibition of lung and liver metastasis by L5178Y-ML25 murine lymphoma cells as well as 
lung metastasis by B16-BL6 murine melanoma cells [104]. The same study showed an inhibitory 
effect by lactoferricin B on both cancer-induced angiogenesis and cancer growth in mice inoculated 
intradermally with B16-BL6 melanoma cells. In addition, intratumoural injections of lactoferricin B 
slow the growth of murine Meth A fibrosarcoma cells grown as subcutaneous cancers in mice [104]. 
Furthermore, oral administration of lactoferricin B to rats that had been injected previously with 
azoxymethane to promote colon carcinogenesis results in an impressive 83% reduction in the incidence 
of colon adenocarcinomas [103]. A similar effect was achieved by oral administration of intact bovine 
lactoferrin, which raises the intriguing possibility that lactoferricin B derived from dietary bovine 
lactoferrin may protect against colon carcinogenesis. Interestingly, consumption of milk and milk 
products has been linked recently to a reduced risk of colorectal cancer in humans [102] as well as 
reduced tumor growth in mice treated with 1,2-dimethylhydrazine to induce colon cancer [107]. 
Not much is known about the mechanism by which lactoferricin B exerts its oncolytic activity, 
although the available evidence favors a direct inhibitory effect of lactoferricin B on cancer cell growth 
and metastasis or induces apoptosis in Jurkat T-leukemia cell lines by affecting the ceramide   
pathway [108,109]. Studies indicate that in vitro exposure to lactoferricin B causes several different 
human leukemia and carcinoma cell lines to lose membrane integrity and eventually lyse [33,104–110]. 
In addition, lactoferricin B is a potent inducer of apoptosis in cultures of THP-1 human monocytic Int. J. Mol. Sci. 2011, 12                 
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leukemia cells [111]. However, the anti tumor activity of lactoferricin B can be inhibited if the 
plasmamembran contains haparan sulfate on its surface [112]. 
3.3. Tachyplesin 
Tachyplesin is a small HDP composed of 17 amino acids and isolated from the horseshoe crab. It 
has an amphipathic structure conferred by two antiparallel β-sheets held rigidly in place by two 
disulfide bonds [113]. A multistep model has been proposed to account for the oncolytic activity of 
tachyplesin [114]. First, tachyplesin binds to hyaluronan (or closely related glycosaminoglycans) on 
the surfaces of the target cells. Second, this bound tachyplesin interacts with C1q in the blood. Third, 
the tachyplesin activates the classic complement pathway. Finally, the formation of the MAC disrupts 
the integrity of the plasma membrane and results in the death of the target cells. Tachyplesin binds to 
both hyaluronan on the cell surface and C1q in the serum and activates the classic complement 
cascade, which damages the integrity of the membranes of the tumor cells resulting in their   
death [114]. The interaction between tachyplesin and hyaluronan could account for the relative 
specificity of oncolytic activity of tachyplesin. Indeed, several studies have shown that many 
malignant cells (bladder, prostate, lung, colon, and breast) express high levels of hyaluronan whereas 
normal tissues express much less [115–117]. In addition, studies have shown that endothelial cells 
involved in neovascularization express high levels of hyaluronan relative to those from established 
blood vessels [118]. The fact that hyaluronan is preferentially expressed on the surfaces of malignant 
and endothelial cells involved in cancer vascularisation could account for the observations that 
tachyplesin inhibits the growth of these cells relative to benign cell lines that express less hyaluronan 
on their surfaces. Tachyplesin has been shown to inhibit malignant growth in the presence of normal 
serum even against cells that overexpress the multiple-drug resistant gene [114]. A synthetic version of 
tachyplesin conjugated to the integrin homing domain RGD blocked the growth of tumor cells both  
in vitro and in vivo [26]. 
RGD-tachyplesin has been shown to inhibit the proliferation of both cultured malignant and 
endothelial cells and reduced the colony formation of TSU cancer cells. In vivo, it has been reported  
to inhibit the growth of neoplasms via induction of apoptosis in both malignant and endothelial cells 
evidenced by activation of several caspases in both the mitochondrial and Fas-dependent pathways [114]. 
4. Hybrid and Synthetic HDPs 
4.1. Buforin II and Buforin IIb 
Buforin II and IIb are HDPs with a helix-hinge-helix structure derived from histone H2A. They 
have a unique mechanism of action as they rapidly crosses bacterial membranes without lysing cells 
and kill by interacting with intracellular macromolecules [119]. Buforin IIb, is a hybrid peptide with 
stronger cytolytic activity against cancer cells than buforin II. Buforin IIb has been shown to display 
strong, selective oncolytic activity against a broad spectrum of cancer cells. Buforin IIb has selective 
oncolytic cell membrane penetration through interaction with gangliosides and then induces apoptosis 
in cancer cells by a mitochondria-dependent pathway, as confirmed by caspase-9 activation and 
cytochrome c release to cytosol as well as by DNA laddering and annexin V staining [120]. Int. J. Mol. Sci. 2011, 12                 
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4.2. Hunter-Killer Peptides 
Some novel peptides, called hunter-killer peptides (HKPs), have been designed to target and then 
kill malignant blood vessels without harming the normal vasculature. They comprise two functional 
domains, one a malignant blood vessel “homing” motif and the other a sequence inducing apoptosis. 
These HKPs home in on the malignant vascular system and therefore offer a less toxic alternative to 
current cancer therapies into native molecules, use of peptomimetics and peptide engineering are   
being developed. Research has also been focused on HKP delivery methods to further enhance the 
potential of these oncolytic HKPs. Furthermore, combination therapies are being developed that take 
advantage of multifunctional HKPs or place different active HKPs together (for example to induce 
apoptosis, necrosis, or immunostimulation), which together represent a novel therapeutic approach for 
oncolytic therapy and, it is anticipated, will develop into an inventive approach to tackle the problem 
of drug resistance [121]. 
Nude mice carrying MDA-MB-435 derived human breast carcinoma xenografts were treated with 
HKP-1 and HKP-2. Malignancies treated by HKP-1 reduced the size of neoplasms were on average  
90% smaller than the size of tumors in the control groups and some of the HKP-1 treated nude mice 
outlived the controls by several months, indicating that both primary neoplasm growth and metastasis 
were inhibited by HKP-1. Lung metastases treated by HKP-1 and HKP-2 were also reduced in number 
and size [27,121]. HKP-3 was evaluated for efﬁcacy in a mouse model of prostate cancer and extended 
the lives of treated mice by up to 2 months longer (nearly one-fifth of their normal life span) than that 
of control treated mice [122]. 
4.3. Polybia-MPI 
Polybia-MPI (IDWKKLLDAAKQIL-NH2, 1.65 kDa) is a HDP from the venom of the social wasp 
Polybia paulista. It has been shown to selectively inhibit the proliferation of prostate and bladder 
cancer cells, but has lower cytotoxicity to normal murine fibroblasts or rat erythrocytes [2,123]. 
Polybia-MPI exerts cytotoxic and antiproliferative efficacy either by membrane disruption or by pore 
formation [2]. Once the bi-layer is disrupted, the transmembrane electrochemical potential collapses 
and cell death occurs in minutes [124]. So the surface charge of cell is important for peptide 
association to the membrane. Malignant cells are negatively charged, so they are prone to bind cationic 
amphipathic antimicrobial peptides. Additionally they have high transmembrane potentials, which can 
be disturbed by destabilization of the membrane, resulting in leaking of electrolytes and consequently, 
leading to cell death. This may explain how polybia-MPI kills the malignant cells. 
Three analogs of polybia-MPI in which Leu7, Ala8 or Asp9 replaced by L-Pro have been designed 
and synthesised and L-Pro substitution of Leu7 or Asp9 significantly reduced the content of alpha-helix 
conformation, and L-Pro substitution of Ala8 can disrupt the alpha-helix conformation thoroughly. The 
L-Pro substitution induces a significant reduction of oncolytic activity, indicating that the alpha-helix 
conformation of polybia-MPI is important for its oncolytic activity [2]. Polybia-MPI demonstrates  
in vitro activity against multi-drug resistant leukemic cell and was able to reduce tumor growth of 
S180 mouse sarcoma after i.p. injection of 10 mg/kg of this peptide [125,126].  
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4.4. Epinecidin-1 
Epinecidin-1 is a synthetic 21-mer antimicrobial peptide originally identiﬁed from Epinephelus 
coioides. Epinecidin-1 contains a prepropeptide of 67 amino acids, and the epinecidin-1 gene is 
composed of three epinecidin-1 peptides from the ﬁsh genome [127,128]. Epinecidin-1 has been 
demonstrated to have in vitro oncolytic and antiproliferative actions against the several cancer cell 
lines including, A549 (human lung carcinoma cell), HeLa (human cervix adenocarcinoma cell), 
HepG2 (human hepatocellular carcinoma cell), HT1080 (human ﬁbrosarcoma cell), U937 (human 
histiocytic lymphoma), NIH3T3 (mouse ﬁbroblast cell), RAW264.7 (mouse macrophage from a tumor 
induced by the Abelson murine leukemia virus), WS-1 (human kidney cell), AML-12 (murine 
hepatocyte cell) and HA59T/VGH (human hepatic tumor-derived cell). Epinecidin-1 has been shown 
to increase the cytotoxicity of these cancer cell lines in dose- and time-dependent manners, indicating 
that cell death occurred by membrane disruption [129,130]. 
4.5. D,L-Amino Acids Host-Defence-like Peptides 
A novel family of antimicrobial peptides was developed, which are composed of Lys and Leu both 
in the forms of D- and L-isomers (diastereomers) [25,131]. It has been found that some of these 
peptides are highly selective towards cancer cell lines compared with normal cells. Most important, 
they could target and arrest the growth of aggressive and hormone-resistant, primary human prostate 
and breast tumors and prevent their experimental and spontaneous metastases, respectively, when 
intratumor [28] or systemically [29] inoculated to immune-deficient mice. These effects were 
correlated with increased necrosis of the tumor cells and a significant decrease in the overall tumor 
microvessel density, as well as newly formed capillary tubes and prostate-specific antigen secretion  
(in prostate tumors). Mode of action studies revealed that the exclusive selectivity of the peptides 
towards cancer derives from their specific binding to surface phosphatidylserine and the killing of the 
cancer cells via cytoplasmic membrane depolarization. Interestingly, the acidic environment created by 
solid tumors could be used as a trigger to activate another family of diastereomeric peptides, by 
making them cationic only at low pH levels. This could be achieved by substituting Lys with His in the 
diastereomeric family of peptides. His is protonated only at acidic pH environments. Such peptides had 
also reduced systemic toxicity [132]. In addition, [D]-K3H3L9 has been demonstrated to induce full 
tumor remission, partial remission or growth reduction in cases of aggressive liposarcomas, synovial 
sarcoma cells or murine fibrosarcoma (BFS-1), when intratumor inoculated to immune-deficient or 
C57BL/6 mice respectively [133,134]. 
d-peptide A, B, C and D are four enantiomeric 9-mer peptides designed and synthesized on the 
basis of 43-mer beetle defensins. These cationic and amphipathic d-9-mer peptides (net charges of +3 
to +5) maintain bacterial membrane disruptive activity similar to the original peptides and have been 
shown to have selective oncolytic activity, against several different cancer cell lines and similar 
antimicrobial mechanisms similar to the original defensins (membrane disruption), but no cytotoxicity 
against mammalian erythrocytes, leucocytes, macrophages and fibroblasts [18,135–138]. 
Overall, diastereomeric peptides have important advantages over native antibacterial and 
conventional peptides therapeutics. These include: (1) Their simple compositions; (2) Their ability to Int. J. Mol. Sci. 2011, 12                 
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preserve activity in serum; (3) They lack the diverse pathological and pharmacological effects 
attributed with peptide therapy; (4) They have very low or no antigenicity; (5) Their lytic mode of 
action makes it difficult for the target to develop resistance. 
5. Discussion 
HDP research is becoming an area of great importance and understanding the role of HDPs in 
humans is in its infancy. The number and types of these HDPs, their tissue specific expression and 
genetic regulation all remain to be addressed. Understanding these aspects may ultimately allow 
manipulation of this arm of the immune system for the benefit of human health, analogous to 
stimulation of the cellular and humoral immune system by vaccination. In particular, the part of the 
arrangement of the phospolipid bilayers of the cells in the biological action of these HDPs continues to 
be contentious. There are a number of actions in which cell membranes may be engaged in the 
functioning of these HDPs. HDPs may form specific holes/channels in the cell membranes, allowing 
seepage of intracellular ions and other cell contents [139–144]. On the other hand, HDPs may cause 
disarray of both cell and mitochondrial membranes through the “carpet” mechanism [145,146]. 
The emergence of resistance to standard chemotherapeutic agents has increased the urgency of 
exploring alternative means of combating neoplasia. HDPs, as oncolytics, have potentially advantageous 
attributes. HDPs are rapidly emerging as attractive candidates for oncolytic treatment. Although many 
HDPs are highly toxic against malignancies cancer in vitro, their potential for applications depends on 
additional features. As a result of their cationic and amphiphilic properties, the peptides may bind to 
host components which reduces their bioavailability and generates harmful side effects, such as lysis of 
red blood cells [147]. This amphipathic design, consisting of spatially separated hydrophobic and 
charged regions, permits intercalation of the HDPs peptide into cell membranes. Their unique 
mechanism of action and ability (in many cases) to kill neoplastic cells makes them attractive prototypes 
for oncolytic drug development. It has also been established that many also have a key modulatory role 
in the innate immune response and form an important link between the innate and adaptive immune 
responses [148]. Owing to their multiple functions, they are considered promising agents for new 
oncolytic therapeutic approaches. Many more HDPs remain to be discovered and this class of 
compounds may soon represent a new weapon against human cancers. 
This manuscript underscores the broad oncolytic potential of HDPs and suggests a new strategy for 
treatment. Future basic and clinical research will tell if and when this new powerful “biological 
weapon” will become part of the health professionals’ armentarium. Further research of HDPs will 
improve our knowledge of their involvement in the recognition and lysis of neoplastic cells, which  
will support the development of new oncolytic therapeutic approaches. A short overview of studied 
HDPs and their potential therapeutic options is given in Table 1. HDP immunomodulating functions 
will become clearer with additional research on structure-function analyses to elucidate their 
mechanisms of action. Most important, future research must take advantage of and build on the diverse 
nature of HDPs and adhere to physiologically relevant conditions, ultimately validating, in vivo, their 
beneficial functions to treat malignancies. 
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Table 1. Evidence for oncolytic properties of HDPs. 
Peptide Cancer  cell  Study  Reference 
Polybia-MPI 
Human bladder and 
prostate 
In vitro, compared against 
murine fibroblasts 
Wang et al. 2008 
Tachyplesin  Prostate cancer cell line 
In vitro and syngenic 
mouse model 
Chen et al. 2001 
Buforin IIb 
62 different cancer  
cell lines 
In vivo mouse xenograft 
model 
 
Bovine lactoferricin 
Human breast cancer  
cell line 
In vitro Furlong  et al. 2006 
Human neuroblastoma  
cell lines 
In vitro and neuroblastoma 
mouse xenograft model 
Eliassen et al. 2006 
Jurkat T-leukemia cells  In vitro Mader  et al. 2007 
adenocarcinoma 
In vivo tumor induced  
F344 rats 
Tsuda et al. 1998 
Human monocytic 
leukemic cells 
In vitro Yoo  et al. 1997 
Cecropin A and B  Bladder cancer cells  In vitro Suttmann  et al. 2008 
Human alpha-defensin-1 
Human lung 
adenocarcinoma 
Mouse xenograft model  Xu et al. 2008 
Human alpha-defensin-1 
and lactoferrin 
oral squamous cell 
carcinoma 
In vitro McKeown  et al. 2006 
Human beta-defensin-1  Prostate cancer cell lines  In vitro Bullard  et al. 2008 
hCAP-18(109–135) 
oral squamous cell 
carcinoma 
In vitro Okumura  et al. 2004 
Magainin II 
Bladder cancer cell line  In vitro Lehmann  et al. 2006 
hematopoietic tumor and 
solid tumor target cells 
In vitro Cruciani  et al. 1991 
Magainin II and 
derivatives 
Several cell lines 
In vivo ovarian  
cancer model 
Baker et al. 1993 
MSI-511 (Magainin 
derivative) 
Several human melanoma 
cell lines 
In vitro Soballe  et al. 1995 
Magainin A and G 
Small cell lung cancer  
cell lines 
In vitro Ohsaki  et al. 1992 
Sythetic 9-mer  
D-peptides 
Mouse myeloma cell line  In vitro Iwasaki  et al. 2009 
CA-ME (hybrid peptide) 
Small cell lung cancer  
cell lines 
In vitro Shin  et al. 1997 
Synthetic L/D-peptides 
Prostate carcinoma  
cell lines 
Mouse xenograft model  Papo et al. 2004 
Primary human prostate 
and breast cancer cells 
Prevents metastases in 
mouse xenograft model 
Papo et al. 2006 
Mouse melanoma and lung 
cancer cell lines 
Mouse xenograft model  Papo et al. 2003 
Human liposarcoma and 
synovial sarcoma cells 
Mouse xenograft model  Steinstraeser et al. 2011 
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6. Conclusion 
It is clear that the enormous potential of HDPs to serve as oncolytic drugs has re-energized the 
scientiﬁc community in the search for better ways to combat malignancies. The effectiveness of any 
targeted therapeutic largely depends on whether the appropriate drug can be delivered to the desired 
location in sufﬁcient quantities and in a timely fashion. Despite many technical hurdles, such as weak 
efﬁciency in vivo and adverse toxicity, HDPs are advantageous because they are small, speciﬁc to 
malignant cells, possess low immunogenicity and are relatively easy to modify and design. HDPs and 
their modiﬁed derivatives will advance to clinical trials. Research must also be focused on HDP 
delivery methods to further enhance their oncolytic potential. Furthermore, combination therapies are 
being developed that take advantage of multifunctional HDPs or place different active HDPs together, 
for example to induce necrosis, apoptosis or immunostimulation, which together represent a novel 
therapeutic approach for oncolytic therapy and, it is hoped, will develop into an innovative approach  
to address the problem of drug resistance. Today’s challenge is to design an oncolytic peptide   
with optimised properties. However, the exploitation of recent insights into cancer biology and   
its microenvironment combined with a multidisciplinary approach involving chemistry, biology,   
high-throughput instrumentation and formulation science will hopefully lead to the discovery of new, 
more-effective, tumor-targeting HDPs.  
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